唑来膦酸预防地舒单抗停药后骨丢失:绝经后女性2年随机试验
这项多中心随机开放标签研究纳入44例长期使用地舒单抗且骨密度T值大于-2.0的绝经后女性,评估停药后使用唑来膦酸预防骨丢失的时机与多次输注需求。结果显示多数无既往双膦酸盐暴露者需多次唑来膦酸输注,而既往暴露者多仅需一次;早期和多次唑来膦酸注射有助于更好地保留骨密度。
要点
- 长期地舒单抗停药后,无既往双膦酸盐暴露者多数需多次唑来膦酸输注(中位2次)。
- 有既往双膦酸盐暴露者多数仅需一次唑来膦酸。
- 地舒单抗停药后早期和多次唑来膦酸注射有助于更好地保留骨密度。
核心结论
- 研究支持长期使用地舒单抗者停药后早期和多次唑来膦酸注射以更好地保留骨密度。
研究设计与样本
- 多中心随机开放标签研究,纳入44例使用地舒单抗超过2年且骨密度T值大于-2.0的绝经后女性。
- 无既往双膦酸盐暴露者随机分为3组:末次地舒单抗后6个月(6M,n=12)或9个月(9M,n=11)接受唑来膦酸,或按CTX>644 ng/l或骨密度下降≥5%时接受唑来膦酸(OBS,n=11)。
- 平行观察组有既往双膦酸盐暴露(OBS-BPs,n=10),按与OBS组相同标准接受唑来膦酸。
- 2年随访期间根据CTX阈值或骨密度丢失标准再次给予唑来膦酸。
主要发现
- 无既往双膦酸盐暴露的地舒单抗停药后患者多数需要多次唑来膦酸输注(中位2次,范围1-5次),而OBS组有既往双膦酸盐暴露者多数仅需一次唑来膦酸。
- 唑来膦酸后12和24个月腰椎骨密度变化中位数在各组间相似。
- 末次地舒单抗剂量效应结束后12个月腰椎骨密度变化在9M组(-8.25%)和OBS组(-8.13%)数值上大于6M组(-4.71%)和OBS-BPs组(-4.62%)。
关键数值与推荐
- 唑来膦酸再给药标准为CTX>644 ng/l或骨密度下降≥5%。
- 共同主要结局为唑来膦酸后1年腰椎骨密度变化和所需唑来膦酸治疗频率。
临床怎么用
- 长期地舒单抗停药后,尤其无既往双膦酸盐暴露者,应考虑早期并可能需要多次唑来膦酸输注以保留骨密度。
- 有既往双膦酸盐暴露者可能仅需一次唑来膦酸,但需根据CTX和骨密度监测决定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This study investigated the timing and effects of zoledronate infusions in long-term denosumab users having reached T-score targets (BMD > -2.0 T-score). Findings support that early and multiple zoledronate injections are needed to preserve as much BMD as possible after stopping denosumab. PURPOSE: This study evaluated the effects of zoledronate (Zol) administration and the need for multiple infusions to prevent bone loss after stopping denosumab (Dmab) in long-term users, and the influence of previous bisphosphonates (BPs) exposure. METHODS: This was a multicentric, randomized, open-label study, including 44 post-menopausal women treated with Dmab > 2 years and reaching BMD T-scores > -2.0. Patients without pre-Dmab BPs were randomized into 3 groups receiving Zol at 6 months (6 M, n = 12) or 9 months (9 M, n = 11) after the last Dmab, or to a group receiving Zol if CTX > 644 ng/l or BMD decreased ≥ 5% (OBS, n = 11). A parallel observational group exposed to pre-Dmab BPs (OBS-BPs, n = 10) received Zol under the same criteria as the OBS group. Zol was re-administered during the 2‑year follow‑up according to CTX threshold or BMD loss criteria. Co-primary outcomes were lumbar spine BMD changes 1-year post-Zol and frequency of Zol treatments required. RESULTS: A majority of post-Dmab patients without previous BPs required multiple Zol infusions (median 2, range 1-5), while most patients in OBS group with previous BPs needed only one Zol. Median LS BMD changes 12 and 24 months post-Zol were similar between groups. However, LS BMD changes at 12 months after the end of the last Dmab dose effect were numerically larger in 9 M group (-8.25%) and OBS group (-8.13%) than in 6 M (-4.71%) and OBS-BPs (-4.62%) groups. CONCLUSION: Findings support that early and multiple Zol injections are needed better to preserve BMD after stopping Dmab in long-term users.
引用
- Ferrari S, Hars M, Biver E, et al. Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates. Osteoporos Int. 2026. PMID: 42366269. doi:10.1007/s00198-026-08115-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。